A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentki w wieku 18 lat i starsze.
- •Zaawansowany rak jajnika, jajowodu lub otrzewnej o wysokim stopniu złośliwości, który nie zareagował na leczenie.
- •Badanie potwierdza obecność białka Cykliny E1 w komórkach nowotworowych.
- •Przeszłe leczenie: choroba odporna na platynę.
- •Liczba wcześniejszych terapii: zwykle od 1 do 3 (może być do 4 w przypadku wcześniejszego leczenia lekiem mirwetuksymab).
- •Wcześniejsze leczenie awastynem (bevacizumabem) jest wymagane, jeśli było wskazane.
- •Wcześniejsze leczenie inhibitorem PARP jest wymagane, jeśli występują mutacje BRCA lub HRD, jeśli było wskazane.
- •Ogólny dobry stan zdrowia i dobre funkcjonowanie narządów.
✗ Disqualifies
- •Rak, który nie reaguje na leczenie platynowe od samego początku.
- •Inne typy raka jajnika lub guzy o innym charakterze.
- •Przeszłe leczenie: niedawna operacja, hospitalizacja, chemioterapia lub inne terapie przeciwnowotworowe.
- •Niedawno przebyta radioterapia lub przeszczep komórek macierzystych.
- •Przyjmowanie innych leków eksperymentalnych w ostatnim czasie.
- •Niezdolność do zaprzestania przyjmowania pewnych leków lub suplementów diety.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 1, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (92)
Site 0170-USA Mitchell Cancer Institute
Mobile, United States
Site 0143 - HonorHealth
Phoenix, United States
Site 0102 - University of Arizona Cancer Center
Tucson, United States
Site 0258 - UC San Diego Moores Cancer Center
La Jolla, United States
Site 0287 - Ridley Tree Cancer Center
Santa Barbara, United States
Site 0135 - Rocky Mountain Cancer Centers
Lone Tree, United States
Site 0158 - Hartford HealthCare
Hartford, United States
Site 0239 - Florida Cancer Specialists - East
Daytona Beach, United States
Site 0241 - Florida Cancer Specialist - North
Lecanto, United States
Site 0173 - Mount Sinai Medical Center
Miami Beach, United States
Site 0308 - Advent Health
Orlando, United States
Site 0108 - Emory University Hospital
Atlanta, United States
Site 0236 - Memorial Health
Savannah, United States
Site 0324 - Illinois Cancer Specialists
Niles, United States
Site 0284 - Community Cancer Center North
Indianapolis, United States
Site 0217 - St Vincent Hospital and Health Care Centers
Indianapolis, United States
Site 0251 - Norton Cancer Institute
Louisville, United States
Site 0146 - Maryland Oncology Hematology, PA
Rockville, United States
Site 0221 - Tufts Medical Center - PPDS
Boston, United States
Site 0104 - Dana Farber Cancer Institute
Boston, United States
Site 0307 - Lahey Hospital and Medical Center
Burlington, United States
Site 0263 - Baystate Medical Center
Springfield, United States
Site 0101 - Barbara Ann Karmanos Cancer Institute
Detroit, United States
Site 0228 - Corewell Health Medical Group West
Grand Rapids, United States
Site 0288 - Minnesota Oncology Hematology - Maplewood
Maplewood, United States
Site 0226 - CoxHealth
Springfield, United States
Site 0317 - Nebraska Methodist Hospital
Omaha, United States
Site 0213 - Center of Hope
Reno, United States
Site 0231 - Northwell Health Cancer Institute
Manhasset, United States
Site 0126 - Wilmot Cancer Center
Rochester, United States
Site 0259 - Duke Cancer Center
Durham, United States
Site 0147 - Trihealth Cancer Institute - Harold and Eugen
Cincinnati, United States
Site 0243 - Mark H Zangmeister Cancer Center
Columbus, United States
Site 0214-Ohio State University Comprehensive Cancer Center
Hilliard, United States
Site 0316 - Willamette Valley Cancer Institute/Oncology Associates of Oregon
Eugene, United States
Site 0232 - University of Pennsylvania
Philadelphia, United States
Site 0178 - Thomas Jefferson University
Philadelphia, United States
Site 0277 - Alliance Cancer Specialist, PC
Wynnewood, United States
Site 0132 - Avera Cancer Institute
Sioux Falls, United States
Site 0103 - University of Texas MD Anderson Cancer Center
Houston, United States
Site 0234 - University of Texas Health, Memorial Hermann Hospital
Houston, United States
Site 0203 - Texas Oncology
Tyler, United States
Site 0295 - Virginia Oncology Associates
Chesapeake, United States
Site 0322 - Inova Schar Cancer Institute
Fairfax, United States
Site 0323 - Compass Oncology
Vancouver, United States
Site 2715 - Icon Cancer Centre - Chermside
Chermside, Australia
Site 2707 - Mater Brisbane
South Brisbane, Australia
Site 2709 - Cancer Research SA
Adelaide, Australia
Site 2702 - Burnside War Memorial Hospital - The Brian Fricker Oncology Centre
Toorak Gardens, Australia
Site 2716 - Epworth Healthcare Freemasons
East Melbourne, Australia
Site 2701 - Sir Charles Gairdner Hospital
Nedlands, Australia
Site 2717 - St John of God Hospital Subiaco
Subiaco, Australia
Site 3102 - Cliniques Universitaires Saint-Luc
Brussels, Belgium
Site 3101 - AZORG - Aalst
Aalst, Belgium
Site 3105 - UZ Leuven
Leuven, Belgium
Site 3616 - Centre Antoine Lacassagne
Nice, France
Site 3611 - ICANS - Institut de cancérologie Strasbourg Europe
Strasbourg, France
Site 3601 - Centre Georges François Leclerc
Dijon, France
Site 3613 - CHRU Besancon - Hopital Jean Minjoz
Besançon, France
Site 3617 - CHU de Brest - Hôpital La Cavale Blanche
Brest, France
Site 3603 - Institut Claudius Regaud
Toulouse, France
Site 3602 - Centre Oscar Lambret
Lille, France
Site 3615 - Hôpital Cochin Port-Royal AP-HP
Paris, France
Site 3614 - Institut de Cancerologie de l'oust
Saint-Herblain, France
Site 3608 - Hospices Civils de Lyon - Hôpital Lyon Sud
Pierre-Bénite, France
Site 3619 - Centre Léon Bérard
Lyon, France
Site 3620 - CHU de Strasbourg - Hopital de Hautepierre
Strasbourg, France
Site 3604 - Institut Gustave Roussy
Villejuif, France
Site 3302 - Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale
Naples, Italy
Site 3308 - Azienda Ospedaliero Universitaria Di Modena Policlinico
Modena, Italy
Site 3312 - Centro di Riferimento Oncologico
Aviano, Italy
Site 3304 - Fondazione Policlinico Universitario A Gemelli
Rome, Italy
Site 3305 - Istituto Europeo di Oncologia
Milan, Italy
Site 3307 - Ospedale San Raffaele S.r.l.
Milan, Italy
Site 3311 - Azienda Ospedaliera Universitaria Integrata Di Verona
Verona, Italy
Site 3303 - Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi-Via Massarenti
Bologna, Italy
Site 2414 - Med-Polonia Sp. z o.o.
Poznan, Poland
Site 2405 - Centrum Badan Klinicznych JCI
Krakow, Poland
Site 2404 - Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
Warsaw, Poland
Site 2419 - Bialostockie Centrum Onkologii im. Marii Sklodowskiej-Curie w Bialymstoku
Bialystok, Poland
Site 2421 - Szpitale Pomorskie Sp. z o. o.
Gdynia, Poland
Site 2908 - National Cancer Center
Goyang-si, South Korea
Site 2905 - Seoul National University Hospital
Seoul, South Korea
Site 2909 - Severance Hospital Yonsei University Health System
Seoul, South Korea
Site 2904 - Asan Medical Center
Seoul, South Korea
Site 2906 - Gangnam Severance Hospital, Yonsei University Health System
Seoul, South Korea
Site 2907 - Samsung Medical Center
Seoul, South Korea
Site 3511 - Instituto de Investigacion Oncologica Vall d'Hebron
Barcelona, Spain
Site 3517 - Clinica Universidad de Navarra
Madrid, Spain
Site 3516 - Hospital Universitario Virgen de La Arrixaca
Murcia, Spain
Site 3501 - Hospital Clinico Universitario de Valencia
Valencia, Spain
Site 3502 - Hospital Universitario La Paz
Madrid, Spain
Trial contact
Project Director
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.